

ALEMBIC LIMITED
Regd.Office: Alembic Road, Vadodara 390 003

AUDITED FINANCIAL RESULTS

FOR THE YEAR ENDED 31ST MARCH, 2012

		Quarter	Quarter	Quarter	Year	₹ in la Year
-						Ended
	No. of the second	Ended	Ended	Ended	Ended	
	Particulars	on 31 st	on 31 st	on 31 st	on 31 st	on 31 st
		March	December	March 2011	March 2012	March 2011
-		(Audited)	2011 (Reviewed)	(Audited)	(Audited)	(Audited)
	ART- I	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
1 (a) Net Sales / Income from Operations	2 224	2.766	4 503	11 704	10.4
	Domestic	2,334	2,766	4,593	11,704	19,4
	Exports	122	255	774	940	2,2
	Total	2,456	3,021	5,367	12,645	21,6
	Less: Excise Duty	243	239	387	1,042	1,6
	Net Sales / Income from Operations	2,213	2,782	4,980	11,603	20,0
(b) Other Operating Income	1	28	71	84	1
_				·		
	otal Income from Operations	2,214	2,810	5,051	11,687	20,1
2	Expenses	(227)	(77)	F20	(2.445)	3
	(a) Decrease/(increase) in stock in trade and work in progress	(337)	(77)	538	(2,445)	
- 25	(b) Consumption of Raw Materials & Packing Materials	1,161	1,320	2,637	7,774	12,6
	(c) Purchase of traded goods					
12	(d) Employees' Cost	379	695	623	2,551	2,9
200	(e) Excise Duty	52	(97)	(40)	151	
Edit X	(f) Other Expenditure	1,026	1,142	871	4,192	3,8
	otal Expenses	2,282	2,983	4,628	12,223	19,8
0.000	rofit from Operations before Other Income, Interest,	(68)	(173)	423	(536)	3
1000	epreciation & Exceptional Items					
4 Di	ividend Income		1	2	565	
5 Ot	ther Income	113	105	59	471	
6 Pr	rofit/(Loss) from Ordinary Activities before Interest,	45	(67)	483	500	55
De	epreciation, & Exceptional Items			-		
7 De	epreclation	257	256	(215)	1,093	1,
8 In	iterest (Net)	133	143	97	520	
	et Profit / (Loss) from Ordinary Activities before xceptional Items	(345)	(466)	601	(1,113)	(6
10 Ex	xceptional Items - Voluntary Retirement Scheme	_		54	248	
11 N	et Profit / (Loss) from Ordinary Activities before Tax	(345)	(466)	547	(1,361)	(1,
12 Ta	ax Expense					
12 '	NAME AND AS AN AS ASSOCIATED AND ASSOCIATED			3	_ [
	Less: Provision for Current / Wealth Tax	(20)	(22)	2	(142)	
	Less/(Add): Provision for Deferred Tax Liability/(Assets)	(36)	(22)	125	(142)	(
	Less/(Add) : Provision of Income Tax of earlier years written back (Net)			277		
13 N	let Profit / (Loss) from Ordinary Activities after Tax	(309)	(444)	142	(1,219)	(1,
100	aid up Equity Share Capital	2,670	2,670	2,670	2,670	2,
	Face value of share ` 2/-)	2,010	2/0/0	2,0.0		A. 500
100	eserves excluding Revaluation Reserve	-		_	5,014	6,
	asic & Diluted EPS (Not Annualised)	(0.23)	(0.33)	0.11	(0.91)	((
	ART- II	(0.20)	(0.00)	0122	(0.007)	
A P	articulars of Shareholding					
1 P	ublic Shareholding					
	- Number of Shares	48777294	48763089	48763089	48777294	4876
	- Percentage of Shareholding	36.53	36.52	36.52	36.53	30
2 P	romoters and Promoter Group Shareholding		-		-	
	- Fully Non - Encumbered					
	- Number of Shares	84738620	84752825	84752825	84738620	8475
	- Percentage of Shares (as a % of the total shareholding	100.00	100.00	100.00	100.00	100
	of promoter and promoter group)	1 255.00	100.00	255.50		-50
	Percentage of Shares (as a % of the total share capital	63.47	63.48	63.48	63.47	6:
	of the Company)	03.47	03.46	05.46	03.47	0
D -		0	anded or 31 at 11	arch 2012		
	NVESTOR COMPLAINTS	Quarter ended on 31st March, 2012				
1	Pending at the beginning of the quarter	e	NIL			
1	Received during the quarter		5			
10	Disposed of during the quarter	1	5 NIL			



Notes:

- 1 The above results have been duly audited by Statutory Auditors, were recommended by the Audit Committee and were approved by the Board of Directors.
- 2 The Company has started a real estate project for residential use. The project is in initial stage and no revenue / profit is recognised in the current quarter / period and therefore, the Company has reported only pharmaceutical segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- 4 There was lack of Government support for levying anti-dumping duty despite efforts of the company. Hence, the company has suspended the production of "Penicillin G" as imports from China have resulted in unviable prices. The company is in process of exploring other alternative options to utilize its manufacturing capacity.

For Alembic Limited

khirayu Amin

Chairman

Place: Vadodara

Date: 2nd May, 2012



Statement of Assets and Lia	₹ in lacs		
Particulars		As at 31st March, 2012	As at 31st March, 2011
A EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital		2,670.40	2,670.40
(b) Reserves and surplus		17,046.45	18,266.20
	Sub-total - Shareholders' funds	19,716.85	20,936.60
2 Non-current liabilities	,		
(a) Other long-term liabilities		3,028,52	75.74
(b) Long-term provisions		98.25	134.60
	Sub-total - Non-current liabilities	3,126.77	210.34
3 Current liabilities			
(a) Short-term borrowings		10,332.77	6,799.54
(b) Trade payables		2,568.02	4,794.28
(c) Other current liabilities		2,780.54	679.14
(d) Short-term provisions	2	624.88	614.03
	Sub-total - Current liabilities	16,306.20	12,886.99
TOTAL - EQUITY AND LIABIL	LITIES	39,149.82	34,033.93
BASSETS			
1 Non-current assets			
(a) Fixed assets	*	19,537.61	20,217.57
(b) Non-current investments		2,342.85	1,623.76
(c) Deferred Tax Assets (net)		197.97	56.24
(d) Long-term loans and adva	inces	70.99	195.51
2 Current assets	Sub-total - Non-current assets	22,149.42	22,093.08
2 Current assets			
(a) Inventories		9,424.82	6,226.40
(b) Trade receivables		1,604.11	4,714.78
(c) Cash and Bank Balance		314.28	302.71
(d) Short-term loans and adva	ances	5,657.19	696.96
	Sub-total - Current assets	17,000.41	11,940.85
TOTAL - ASSETS		39,149.82	34,033.93
	F		

For Alembic Limited

Chirayu Amin Chairman